How India Exports Tenofovir to the World

Tenofovir, a key antiretroviral agent, has been widely approved in the United States through numerous Abbreviated New Drug Applications (ANDAs). According to the FDA's Orange Book, multiple generic versions of tenofovir disoproxil fumarate have received approval, facilitating broad access to this essential medication. Notably, on March 24, 2010, the FDA approved Viread (tenofovir disoproxil fumarate) for the treatment of HIV infection in combination with other antiretroviral agents in patients aged 12 to less than 18 years. This approval was granted orphan drug designation on March 17, 2009, underscoring its importance in pediatric HIV treatment.

The substantial number of approved ANDAs reflects a competitive market landscape, aligning with the presence of 296 active Indian exporters of tenofovir. This robust exporter base underscores India's significant role in supplying tenofovir to the U.S. market. As of the current date, there are no active FDA import alerts specifically targeting tenofovir products from India, indicating compliance with U.S. regulatory standards.

In the European Union, tenofovir-containing products have secured marketing authorizations through the European Medicines Agency (EMA). For instance, Emtricitabine/Tenofovir disoproxil Zentiva received EU-wide approval on November 9, 2016, for the treatment of HIV-1 infection. (ema.europa.eu) Similarly, Emtricitabine/Tenofovir alafenamide Viatris was authorized on July 18, 2025, expanding treatment options for HIV-1 infected adults and adolescents. (ema.europa.eu)

The United Kingdom, through the Medicines and Healthcare products Regulatory Agency (MHRA), adheres to stringent guidelines for the approval of antiretroviral medications, ensuring that tenofovir products meet high standards of safety, efficacy, and quality. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers, encompassing rigorous quality control measures and regular inspections to maintain product integrity.

Tenofovir is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its critical role in global health. The WHO Prequalification Programme has also assessed and prequalified various tenofovir products, ensuring they meet international standards for quality, safety, and efficacy. Additionally, tenofovir formulations are standardized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), facilitating consistent quality benchmarks worldwide.

In India, tenofovir is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for tenofovir formulations to ensure affordability; for example, the ceiling price for tenofovir disoproxil fumarate 300 mg tablets was established in March 2025. Export of tenofovir from India requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of pharmaceutical exports.

The primary patents for tenofovir have expired, leading to increased generic competition and a diversified market. This has enabled numerous manufacturers, including Indian pharmaceutical companies, to produce and export tenofovir, contributing to its widespread availability and affordability globally.

In August 2025, the EMA granted marketing authorization for Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, expanding treatment options for HIV-1 infection. (ema.europa.eu) In July 2025, the EMA approved Emtricitabine/Tenofovir alafenamide Viatris for the treatment of HIV-1 infection in adults and adolescents. (ema.europa.eu) In June 2025, the EMA adopted a positive opinion for Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, recommending its approval for HIV-1 treatment. (ema.europa.eu) In May 2025, the EMA adopted a positive opinion for Emtricitabine/Tenofovir alafenamide Viatris, recommending its approval for HIV-1 treatment. (ema.europa.eu) In March 2025, the NPPA revised the ceiling price for tenofovir disoproxil fumarate 300 mg tablets to enhance affordability.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), with approximately 60–70% of these materials imported from China. This dependency poses significant risks, as disruptions in Chinese supply chains can directly impact India's pharmaceutical production. For instance, environmental regulations in China have led to the shutdown of several chemical manufacturing units, causing supply uncertainties and price volatility for Indian pharmaceutical companies.

To mitigate these risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, this initiative has resulted in the establishment of manufacturing capacity for 26 KSMs/APIs, leading to cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

The Tenofovir export market is highly concentrated, with the top five exporters accounting for 95.3% of the market share. MACLEODS PHARMACEUTICALS LTD alone holds a 75.1% share, indicating a significant single-source risk. Any operational disruptions within these key suppliers could severely impact the global availability of Tenofovir.

The PLI Scheme for Pharmaceuticals, launched in March 2021, aims to diversify the supplier base by encouraging new entrants and expanding existing capacities. The scheme has a financial outlay of ₹6,940 crore and covers 41 products, including critical KSMs, DIs, and APIs. However, the effectiveness of this scheme in reducing supplier concentration for Tenofovir remains to be fully realized.

Geopolitical tensions and shipping disruptions pose additional risks to the Tenofovir supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical exports; any instability in these regions can lead to delays and increased shipping costs. Furthermore, escalating tensions between the U.S. and China have the potential to disrupt global trade dynamics, affecting the availability of raw materials and finished products.

Regulatory bodies such as the FDA and EMA have issued shortage alerts for various medications in the past, highlighting the vulnerability of pharmaceutical supply chains to geopolitical and logistical challenges. While specific alerts for Tenofovir have not been reported recently, the interconnected nature of global supply chains necessitates proactive risk management strategies.

• Diversify Supplier Base: Encourage the development of additional manufacturing facilities for Tenofovir and its raw materials to reduce reliance on a limited number of suppliers.

• Enhance Domestic Production: Leverage government initiatives like the PLI Scheme to boost domestic manufacturing of critical KSMs and APIs, thereby reducing dependency on imports.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to detect early signs of supply disruptions, enabling timely interventions.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to mitigate the impact of geopolitical tensions on key maritime routes.

• Engage in Strategic Stockpiling: Maintain strategic reserves of Tenofovir and its raw materials to buffer against potential supply chain disruptions.

RISK_LEVEL: MEDIUM